APA

Oxnard G. R., Yang J. C., Yu H., Kim S., Saka H., Horn L., Goto K., Ohe Y., Mann H., Thress K. S., Frigault M. M., Vishwanathan K., Ghiorghiu D., Ramalingam S. S. & Ahn M. (20210106). TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Oxnard G R, Yang J C-H, Yu H, Kim S-W, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress K S, Frigault M M, Vishwanathan K, Ghiorghiu D, Ramalingam S S and Ahn M-J. 20210106. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Oxnard G. R., Yang J. C., Yu H., Kim S., Saka H., Horn L., Goto K., Ohe Y., Mann H., Thress K. S., Frigault M. M., Vishwanathan K., Ghiorghiu D., Ramalingam S. S. and Ahn M. (20210106). TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Oxnard G R, Yang J C-H, Yu H, Kim S-W, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress K S, Frigault M M, Vishwanathan K, Ghiorghiu D, Ramalingam S S and Ahn M-J. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. : Annals of oncology : official journal of the European Society for Medical Oncology. 20210106.